Sofinnova leads €26.5m round for EryDel

Existing shareholders Genextra and Innogest also took part in the investment round.

With the fresh capital, the Italian biotech company, which specialises in drug delivery through red blood cells, will boost its international development. It also aims to complete the Attest trial, a phase-III clinical trial currently enrolling in Europe, Asia, Australia and the US.

Paris-based Sofinnova closed its eighth main fund on €300m, exceeding the €250m target, in late 2015.

Previous funding
Innogest, via Fondo Innogest Capital, and Banca Marche, via Fondo Focus Impresa, invested €2.5m in the first round of funding for EryDel in September 2008.

Genextra, a life sciences company, led a €15m series-B round of financing in EryDel in July 2013, along with existing investors. The funding was earmarked for the planned development in the treatment of neurological symptoms of ataxia telangiectasia, a rare autosomal recessive disorder.

Company
Founded in 2007 and headquartered in Urbino, EryDel is a biotechnology company specialised in the development of drugs and diagnostics delivered through red blood cells by using a proprietary medical device technology. 

People
Sofinnova Partners – Graziano Seghezzi (managing partner).
EryDel – Luca Benatti (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Southern Europe
• Healthcare
• Italy
• Sofinnova Partners
• Venture